Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) have received a consensus rating of “Moderate Buy” from the eight research firms that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $52.00.

A number of research analysts recently issued reports on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday, October 8th. The Goldman Sachs Group upped their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Wells Fargo & Company boosted their price objective on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a research report on Thursday, September 25th. Finally, Citigroup upped their price objective on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, October 17th.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 50,490 shares of the company’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $38.87, for a total transaction of $1,962,546.30. Following the transaction, the chief accounting officer directly owned 27,046 shares in the company, valued at approximately $1,051,278.02. This represents a 65.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Barry D. Quart sold 20,129 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $41.51, for a total transaction of $835,554.79. Following the sale, the director owned 12,546 shares of the company’s stock, valued at approximately $520,784.46. This represents a 61.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 511,057 shares of company stock valued at $19,972,512 over the last 90 days. Corporate insiders own 53.48% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Rubric Capital Management LP increased its holdings in Kiniksa Pharmaceuticals International by 2.3% in the third quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock valued at $155,320,000 after purchasing an additional 90,194 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of Kiniksa Pharmaceuticals International by 22.6% in the 2nd quarter. Acadian Asset Management LLC now owns 1,267,989 shares of the company’s stock valued at $35,067,000 after acquiring an additional 233,668 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of Kiniksa Pharmaceuticals International by 45.3% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock valued at $41,481,000 after acquiring an additional 332,846 shares during the last quarter. Qube Research & Technologies Ltd raised its position in shares of Kiniksa Pharmaceuticals International by 277.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after acquiring an additional 653,236 shares during the period. Finally, Millennium Management LLC boosted its stake in Kiniksa Pharmaceuticals International by 8.7% during the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after acquiring an additional 67,452 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA opened at $42.00 on Wednesday. The company has a market capitalization of $3.18 billion, a P/E ratio of 93.34 and a beta of 0.02. Kiniksa Pharmaceuticals International has a one year low of $17.82 and a one year high of $44.42. The business’s 50 day simple moving average is $40.64 and its 200-day simple moving average is $35.47.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). The business had revenue of $180.86 million for the quarter, compared to analyst estimates of $166.64 million. Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The company’s revenue for the quarter was up 61.2% on a year-over-year basis. During the same period in the prior year, the business earned ($0.18) earnings per share. On average, sell-side analysts anticipate that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.